INTERVENTION 1:	Intervention	0
HER2+ TC	Intervention	1
Participants with HER2+ breast cancer received treatment as follows:	Intervention	2
breast cancer	DOID:1612	24-37
Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.	Intervention	3
day	UO:0000033	55-58
day	UO:0000033	165-168
doxorubicin	CHEBI:28748,BAO:0000639	104-115
paclitaxel	CHEBI:45863	135-145
Cycles 4-7 (3-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.	Intervention	4
paclitaxel	CHEBI:45863	53-63
day	UO:0000033	83-86
Cycles 8-10 (3-week cycles): trastuzumab 6 mg/kg, IV, on Day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on Days 1 and 8, followed by 2 weeks off.	Intervention	5
day	UO:0000033	57-60
day	UO:0000033	185-188
cyclophosphamide	CHEBI:4026	67-83
methotrexate	CHEBI:44185	100-112
5-fluorouracil	CHEBI:46345	132-146
Cycles 11-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years.	Intervention	6
day	UO:0000033	95-98
day	UO:0000033	203-206
adjuvant	CHEBI:60809	177-185
tamoxifen	CHEBI:41774	186-195
INTERVENTION 2:	Intervention	7
HER2+ C	Intervention	8
Participants with HER2+ breast cancer received treatment as follows:	Intervention	9
breast cancer	DOID:1612	24-37
Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.	Intervention	10
doxorubicin	CHEBI:28748,BAO:0000639	28-39
paclitaxel	CHEBI:45863	58-68
day	UO:0000033	88-91
Cycles 4-7 (3-week cycles): paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.	Intervention	11
paclitaxel	CHEBI:45863	28-38
day	UO:0000033	58-61
Cycles 8-10 (3-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, on Days 1 and 8, followed by 1 week off.	Intervention	12
cyclophosphamide	CHEBI:4026	29-45
methotrexate	CHEBI:44185	62-74
5-fluorouracil	CHEBI:46345	94-108
week	UO:0000034	15-19
week	UO:0000034	156-160
Inclusion Criteria:	Eligibility	0
female patients, >=18 years of age, with locally advanced breast cancer.	Eligibility	1
female	PATO:0000383	0-6
age	PATO:0000011	31-34
breast cancer	DOID:1612	58-71
Exclusion Criteria:	Eligibility	2
previous therapy for any invasive malignancy.	Eligibility	3
Outcome Measurement:	Results	0
Event-Free Survival (EFS) - Percentage of Participants With an Event	Results	1
EFS was defined as the time between randomization and date of documented occurrence of disease recurrence or progression (local, regional, distant or contralateral) or death due to any cause.	Results	2
time	PATO:0000165	23-27
disease	DOID:4,OGMS:0000031	87-94
death	OAE:0000632	168-173
Time frame: Baseline (BL), Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter	Results	3
time	PATO:0000165	0-4
day	UO:0000033	39-42
day	UO:0000033	62-65
day	UO:0000033	103-106
drug	CHEBI:23888	180-184
Results 1:	Results	4
Arm/Group Title: HER2+ TC	Results	5
Arm/Group Description: Participants with HER2+ breast cancer received treatment as follows:	Results	6
breast cancer	DOID:1612	47-60
Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.	Results	7
day	UO:0000033	55-58
day	UO:0000033	165-168
doxorubicin	CHEBI:28748,BAO:0000639	104-115
paclitaxel	CHEBI:45863	135-145
Cycles 4-7 (3-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.	Results	8
paclitaxel	CHEBI:45863	53-63
day	UO:0000033	83-86
Cycles 8-10 (3-week cycles): trastuzumab 6 mg/kg, IV, on Day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on Days 1 and 8, followed by 2 weeks off.	Results	9
day	UO:0000033	57-60
day	UO:0000033	185-188
cyclophosphamide	CHEBI:4026	67-83
methotrexate	CHEBI:44185	100-112
5-fluorouracil	CHEBI:46345	132-146
Cycles 11-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years.	Results	10
day	UO:0000033	95-98
day	UO:0000033	203-206
adjuvant	CHEBI:60809	177-185
tamoxifen	CHEBI:41774	186-195
Overall Number of Participants Analyzed: 115	Results	11
Measure Type: Number	Results	12
Unit of Measure: percentage of participants  40.0	Results	13
Results 2:	Results	14
Arm/Group Title: HER2+ C	Results	15
Arm/Group Description: Participants with HER2+ breast cancer received treatment as follows:	Results	16
breast cancer	DOID:1612	47-60
Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.	Results	17
doxorubicin	CHEBI:28748,BAO:0000639	28-39
paclitaxel	CHEBI:45863	58-68
day	UO:0000033	88-91
Cycles 4-7 (3-week cycles): paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.	Results	18
paclitaxel	CHEBI:45863	28-38
day	UO:0000033	58-61
Cycles 8-10 (3-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, on Days 1 and 8, followed by 1 week off.	Results	19
cyclophosphamide	CHEBI:4026	29-45
methotrexate	CHEBI:44185	62-74
5-fluorouracil	CHEBI:46345	94-108
week	UO:0000034	15-19
week	UO:0000034	156-160
Overall Number of Participants Analyzed: 116	Results	20
Measure Type: Number	Results	21
Unit of Measure: percentage of participants  50.9	Results	22
Adverse Events 1:	Adverse Events	0
Total: 18/115 (15.65%)	Adverse Events	1
Febrile neutropenia * 7/115 (6.09%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Neutropenia * 1/115 (0.87%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	0-11
Pancytopenia * 1/115 (0.87%)	Adverse Events	4
pancytopenia	HP:0001876,DOID:12450	0-12
Diarrhoea * 0/115 (0.00%)	Adverse Events	5
Nausea * 0/115 (0.00%)	Adverse Events	6
nausea	HP:0002018	0-6
Stomatitis * 0/115 (0.00%)	Adverse Events	7
stomatitis	HP:0010280,DOID:9637	0-10
Vomiting * 1/115 (0.87%)	Adverse Events	8
vomiting	HP:0002013	0-8
Asthenia * 1/115 (0.87%)	Adverse Events	9
asthenia	HP:0025406	0-8
Mucosal inflammation * 0/115 (0.00%)	Adverse Events	10
Pyrexia * 3/115 (2.61%)	Adverse Events	11
Gastrointestinal infection * 1/115 (0.87%)	Adverse Events	12
Adverse Events 2:	Adverse Events	13
Total: 8/112 (7.14%)	Adverse Events	14
Febrile neutropenia * 3/112 (2.68%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	8-19
Neutropenia * 2/112 (1.79%)	Adverse Events	16
neutropenia	HP:0001875,DOID:1227	0-11
Pancytopenia * 0/112 (0.00%)	Adverse Events	17
pancytopenia	HP:0001876,DOID:12450	0-12
Diarrhoea * 2/112 (1.79%)	Adverse Events	18
Nausea * 2/112 (1.79%)	Adverse Events	19
nausea	HP:0002018	0-6
Stomatitis * 1/112 (0.89%)	Adverse Events	20
stomatitis	HP:0010280,DOID:9637	0-10
Vomiting * 1/112 (0.89%)	Adverse Events	21
vomiting	HP:0002013	0-8
Asthenia * 0/112 (0.00%)	Adverse Events	22
asthenia	HP:0025406	0-8
Mucosal inflammation * 1/112 (0.89%)	Adverse Events	23
Pyrexia * 0/112 (0.00%)	Adverse Events	24
Gastrointestinal infection * 0/112 (0.00%)	Adverse Events	25
